Gardnerella Vaginolysin Potentiates Glycan Molecular Mimicry by Neisseria gonorrhoeae.
Gardnerella
bacterial vaginosis
complement
cytolysin
factor H
gonorrhea
sialic acid
vaginolysin
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
14
04
2023
accepted:
13
09
2023
pmc-release:
18
09
2024
medline:
29
11
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
ppublish
Résumé
Bacterial vaginosis (BV) is a dysbiotic condition of the vaginal microbiome associated with higher risk of infection by Neisseria gonorrhoeae-the cause of gonorrhea. Here we test if one known facet of BV-the presence of bacterial cytolysins-leads to mobilization of intracellular contents that enhance gonococcal virulence. We cloned and expressed recombinant vaginolysin (VLY), a cytolysin produced by the BV-associated bacterium Gardnerella, verifying that it liberates contents of cervical epithelial (HeLa) cells, while vector control preparations did not. We tested if VLY mediates a well-known gonococcal virulence mechanism-the molecular mimicry of host glycans. To evade host immunity, N. gonorrhoeae caps its lipooligosaccharide (LOS) with α2-3-linked sialic acid. For this, gonococci must scavenge a metabolite made inside host cells. Flow cytometry-based lectin-binding assays showed that gonococci exposed to vaginolysin-liberated contents of HeLa cells displayed greater sialic acid capping of their LOS. This higher level of bacterial sialylation was accompanied by increased binding of the complement regulatory protein factor H, and greater resistance to complement attack. Together these results suggest that cytolytic activities present during BV may enhance the ability of N. gonorrhoeae to capture intracellular metabolites and evade host immunity via glycan molecular mimicry.
Identifiants
pubmed: 37722688
pii: 7276580
doi: 10.1093/infdis/jiad391
pmc: PMC10681867
doi:
Substances chimiques
N-Acetylneuraminic Acid
GZP2782OP0
Bacterial Proteins
0
Complement Factor H
80295-65-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610-1620Subventions
Organisme : NIAID NIH HHS
ID : R01 AI160247
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. S. R. is a cofounder of STIRx, Inc. All other authors declare no conflict of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
J Biol Chem. 2013 Apr 26;288(17):12067-79
pubmed: 23479734
J Biol Chem. 2011 Jun 24;286(25):22235-42
pubmed: 21531728
Clin Infect Dis. 2018 Jan 18;66(3):437-443
pubmed: 29136127
J Infect Dis. 2020 Oct 13;222(10):1641-1650
pubmed: 32692363
Sex Transm Dis. 2007 Nov;34(11):864-9
pubmed: 17621244
Evol Appl. 2019 Jan 03;12(2):337-349
pubmed: 30697344
J Infect Dis. 1999 Dec;180(6):1863-8
pubmed: 10558942
Infect Immun. 2013 Dec;81(12):4544-50
pubmed: 24082080
J Exp Med. 1998 Mar 2;187(5):743-52
pubmed: 9480984
Am J Med. 1983 Jan;74(1):14-22
pubmed: 6600371
PLoS Pathog. 2015 Dec 02;11(12):e1005290
pubmed: 26630657
Clin Infect Dis. 2019 Oct 15;69(9):1621-1623
pubmed: 30778532
Pathog Dis. 2017 Jun 1;75(4):
pubmed: 28460033
PLoS One. 2012;7(6):e37818
pubmed: 22719852
J Infect Dis. 2010 Dec 15;202(12):1907-15
pubmed: 21067371
Biomolecules. 2012 Feb 07;2(1):46-75
pubmed: 24970127
Sci Rep. 2022 Jul 26;12(1):12757
pubmed: 35882911
J Exp Med. 1990 May 1;171(5):1649-64
pubmed: 1692081
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Mil Med Res. 2016 Feb 13;3:4
pubmed: 26877884
J Infect Dis. 2016 Dec 1;214(11):1621-1628
pubmed: 27471322
Front Cell Infect Microbiol. 2020 Apr 24;10:168
pubmed: 32391287
Pathogens. 2021 Jan 20;10(2):
pubmed: 33498226
Infect Chemother. 2015 Mar;47(1):60-3
pubmed: 25844265
Immunobiology. 1993 Apr;187(3-5):382-402
pubmed: 8330904
J Bacteriol. 2011 Mar;193(5):1034-41
pubmed: 21169489
Front Immunol. 2022 Aug 30;13:975676
pubmed: 36110842
Infect Immun. 2005 Nov;73(11):7390-7
pubmed: 16239538
Front Cell Infect Microbiol. 2013 Nov 19;3:80
pubmed: 24312900
Ann Epidemiol. 2012 Mar;22(3):213-20
pubmed: 22192490
PLoS One. 2016 Jan 11;11(1):e0146510
pubmed: 26751374
Front Cell Infect Microbiol. 2021 Apr 07;11:631972
pubmed: 33898328
Clin Microbiol Rev. 2004 Oct;17(4):965-81, table of contents
pubmed: 15489357